Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough.

Chinese journal of cancer - 18 Jul 2015

Zhou Fei, Zhou Cai-Cun

Abstract excerpt

Historically, non-small cell lung cancer (NSCLC) is divided into squamous and nonsquamous subtypes based on histologic features. With a growing number of oncogenic drivers being identified in squamous and nonsquamous NSCLC, this malignancy has been recently divided into several distinct subtypes according to the specific molecular alterations. This new paradigm has substantially highlighted the treatment of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to EGFR gene

Share to Lung Neoplasms

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 26187152
DOI: 10.1186/s40880-015-0036-4
PMCID: PMC4593374

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough.PMID 26187152Read ↗

Targeted therapy for non-small-cell lung cancer: past, present and future.Semantic proximity Read ↗

Cutting edge therapies: A review of Food and Drug Administration-approved drugs for non-small cell lung cancer.Semantic proximity Read ↗

Targeted therapy for lung cancer: Beyond EGFR and ALK.Semantic proximity Read ↗

Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary managementSemantic proximity Read ↗

Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

Targeted Therapy for Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Updates in the Management of EGFR-Mutated Non-small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.Semantic proximity Read ↗

Non-small cell lung cancer: an update on emerging EGFR-targeted therapies.Semantic proximity Read ↗

Emerging targeted therapies in non-small cell lung cancer.Semantic proximity Read ↗

Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.Semantic proximity Read ↗

New and emerging targeted treatments in advanced non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.